cyclophosphamide / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1110 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cyclophosphamide / Generic mfg.
AVALON, NCT05243524: Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Terminated
2b
16
Canada, US
Maveropepimut-S, MVP-S, DPX-Survivac, Cyclophosphamide 50mg, CPA, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Platinum-resistant Epithelial Ovarian Cancer
07/23
08/23
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
ACTRN12622000530729: Autologous Stem Cell Transplant in other Neuro-Inflammatory diseases

Not yet recruiting
2
20
 
St Vincent's Hospital, Sydney , St Vincent's Hospital,Sydney
Neuromyelitis Optica, Stiff Person Syndrome, Myasthenia Gravis, Central Nervous System Vasculitis
 
 
ACTRN12613001154796: A phase 2 trial of a preventative treatment (cyclophosphamide) for graft-versus-host disease after matched (HLA-identical) allogeneic donor transplant using less intensive chemotherapy

Not yet recruiting
2
24
 
Westmead Hospital, Westmead Hospital
Graft versus Host Disease, Haematological malignancy
 
 
ACTRN12605000731695: Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer

Not yet recruiting
2
30
 
Mater Adult hospital, Mater Adult Hospital
Breast Cancer
 
 
ACTRN12622000207718p: A study of a chemotherapy regime and tislelizumab in elderly patients with Hodgkin Lymphoma

Not yet recruiting
2
35
 
Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group (ALLG)
Hodgkin Lymphoma
 
 
ACTRN12608000013369: Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response

Not yet recruiting
2
37
 
Royal Women's Hospital, Royal Women's Hospital
Recurrent Ovarian Cancer
 
 
ACTRN12621001529831p: NHL35: A study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for patients with primary mediastinal B-Cell lymphoma.

Not yet recruiting
2
43
 
Australasian Lymphoma and Leukaemia Group, Australasian Leukaemia and Lymphoma Group
Primary mediastinal B-cell lymphoma
 
 
2017-002264-41: NA NA

Not yet recruiting
2
52
Europe
Remicade 100 mg, cyclophosphamide, Powder for solution for infusion, Remicade 100 mg, cyclophosphamide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS
Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease, Behcet disease maladie de Behcet, Diseases [C] - Immune System Diseases [C20]
 
 
ACTRN12611000826943: Long term follow up of patients with severe Systemic Sclerosis (SSc) and Rheumatoid Arthritis (RA) who have undergone Haematopoietic Stem Cell Transplantation (HSCT).

Recruiting
2
25
 
St Vincents Hospital, Sydney, St. Vincents Hospital, Sydney., Haematology Department, St Vincents Hospital, Sydney
Systemic Sclerosis and Rheumatoid Arthritis
 
 
ACTRN12608000129381: Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse

Recruiting
2
40
 
Huisheng Ai, Affiliated Hospital of Academy of Military Medicine Science
High-risk acute leukemia patients
 
 
ACTRN12619000348156: Autologous Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis.

Recruiting
2
50
 
Alfred Health, Alfred Health
Relapsing Remitting Multiple Sclerosis
 
 
ACTRN12606000030572: An open label phase 2 study of doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) delivered every 14 days with pegfilgrastim and darbepoetin alfa support for the adjuvant treatment of women with breast cancer

Recruiting
2
80
 
Amgen Australia, Amgen Australia
Early stage breast cancer
 
 
ACTRN12609001059257: Women undergoing chemotherapy plus gonadotrophin-releasing hormone (GnRH) analouges compared with control to protect ovairan function

Recruiting
2
100
 
Ass. Prof. Dr. Eman Elgindy, Zagazig University School of Medicine, Alexandria Regional center for Women Health
Women of reproductive age receiving chemotherapy, Cancer
 
 
ACTRN12608000639325: Multicentre clinical study with early treatment intensification in patients with high-risk Hodgkin Lymphoma, identified as 18-F Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) scan positive after two conventional Doxorubicin, Bleomycin, Vinblastine, Dacarbazine (ABVD) courses

Recruiting
2
450
 
Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Gruppo Italiano Terapia Innovativa nei Linfomi
Hodgkin Lymphoma
 
 
ACTRN12613000339752: A Single Centre Phase II Study Of Haematopoietic Stem Cell Transplantation (HSCT) for Severe Auto-Immune Diseases.

Recruiting
2
150
 
St Vincent's Hospital, Sydney, St Vincent's Hospital, Sydney
Auto Immune disorders
 
 
ACTRN12617000151336: A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis

Recruiting
2
70
 
St Vincent's Hospital Sydney, Arrow Bone Marrow Transplant Foundation
Acute Myeloid Leukaemia in first or second complete remission, Chronic Myeloid Leukaemia prior to acute or blast transformation, acute Lymphoblastic Leukaemia in first or second complete remission, Non Hodgkin's Disease in remission, for Hodgkins Disease in remission, Myeloproliferative disease , Patient requiring a haplo-identical stem cell tranplant for Myelodysplastic syndrome with less than or equal 2 CIBMTR risk factors , transformed Acute Myeloid Leukaemia with less than or equal 2 CIBMTR risk factors , MDSIPSS, Acute Myeloid Leukaemia refractory disease with less than or equal 2 CIBMTR
 
 
ACTRN12616000151437: A Phase II study: Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis .

Recruiting
2
20
 
Austin Health, Austin Health
Relapsing Remitting Multiple Sclerosis
 
 
ACTRN12617000216314: A Phase II dose escalation study of cyclophosphamide in haematopoietic stem cell transplantation in severe systemic sclerosis patients unfit for standard dose cyclophosphamide.

Recruiting
2
15
 
St Vincent's Hospital Sydney, NSW Health
Autoimmune disorder , systemic sclerosis
 
 
jRCTs041210104: Multicenter clinical trial to evaluate the efficacy of rituximab combination chemotherapy for children or AYAswith localized mature B-cell lymphoma

Recruiting
2
100
Japan
Rituxan (rituximab) - Roche, cyclophosphamide - Generic mfg., vincristine - Generic mfg.
National Hospital Organization Nagoya Medical Center
Mature B-cell lymphoma
 
 
ACTRN12622000536763: Autologous Stem Cell Transplant in Multiple Sclerosis

Recruiting
2
30
 
St Vincent's Hospital, Sydney , St Vincent's Hospital,Sydney
Multiple Sclerosis
 
 
ACTRN12621001529831: NHL35: A study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for patients with primary mediastinal B-Cell lymphoma.

Recruiting
2
35
 
Australasian Lymphoma and Leukaemia Group, Australasian Leukaemia and Lymphoma Group
Primary mediastinal B-cell lymphoma
 
 
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer

Ongoing
2
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg.
Remegen Biopharmaceutical (Yantai) Co., Ltd
HR-negative, HER2-low breast cancer
 
 
ACTRN12622000207718: A study of a chemotherapy regime and tislelizumab in elderly patients with Hodgkin Lymphoma

Recruiting
2
35
 
Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group (ALLG)
Hodgkin Lymphoma
 
 
ACTRN12623000292673: A multi-centre Phase 2 study exploring optimal dosing and scheduling of cyclophosphamide in systemic sclerosis patients undergoing haematopoietic stem cell transplantation.

Recruiting
2
40
 
St Vincent's Hospital, Sydney , St Vincent's Hospital, Sydney
systemic sclerosis
 
 
ACTRN12622001232729: A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation

Recruiting
2
127
 
St Vincent's Hospital, Sydney , St Vincent's Hospital, Sydney , Arrow Bone Marrow Transplant Foundation , Link (A Clinigen Company)
Acute Myeloid Leukaemia , Chronic Myeloid Leukaemia , Acute Lymphoblastic Leukaemia , Non Hodgkin's Disease , Hodgkin's Disease , transformed AML/ MDS , Myeloproliferative Disorders
 
 
ChiCTR2100054451: Phase II clinical study of tislelizumab combined with R-CHOP in the first-line treatment of unspecified EBV-positive diffuse large B-cell lymphoma

Recruiting
2
26
China
Tislelizumab combined with R-CHOP
Fudan University Cancer Hospital ; Fudan University Cancer Hospital, BeiGene
EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL)
 
 
NCT00006256: Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer

Completed
2
44
US
paclitaxel, adjuvant therapy, radiation therapy
Case Comprehensive Cancer Center
Breast Cancer
11/05
11/23
2006-004478-29: DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND PHARMACOGENETIC EVALUATIONS DOCETAXEL E PREDNISONE IN ASSOCIAZIONE A TERAPIA METRONOMICA CON CICLOFOSFAMIDE E CELECOXIB IN PAZIENTI CON CARCINOMA PROSTATICO ORMONO-REFRATTARIO : STUDIO CLINICO DI FASE II CON VALUTAZIONE FARMACODINAMICA E FARMACOCINETICA

Ongoing
2
45
Europe
Solution for infusion, Tablet, TAXOTERE, DELTACORTENE, ENDOXAN BAXTER, CELEBREX
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
PATIENTS WITH PROSTATIC HORMONE-REFRACTORY CANCER PAZIENTI AFFETTI DA CA PROSTATICO ORMONOREFRATTARIO, Diseases [C] - Cancer [C04]
 
 
NCT00544115: Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting
2
260
NA
busulfan, cyclophosphamide, cyclosporine, etoposide, fludarabine phosphate, melphalan, methotrexate, mycophenolate mofetil, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
City of Hope Medical Center, National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition
03/07
12/24
ACTRN12616000786493: Phase II study of Paclitaxel and Epirubicin as Neoadjuvant Treatment for locally advanced Breast Cancer.

Active, not recruiting
2
40
 
The Queen Elizabeth Hospital, Bristol-Myers Squibb Pty Ltd, The Queen Elizabeth Hospital
Breast Cancer
 
 
NCT00244036: Single or Double Umbilical Cord Blood Unit Transplantation Followed by GVHD Prophylaxis With FK506 and MMF

Active, not recruiting
2
49
US
Umbilical Cord Blood Transplant, GVHD prophylaxis with Tacrolimus and Mycophenolate Mofetil, FK 506, MMF, cellcept
Vanderbilt University
Cord Blood Stem Cell Transplantation
09/09
09/09
NCT00261651: Phase II Study for Patients With Relapsed Primary Central Nervous System Lymphoma

Active, not recruiting
2
3
US
rituximab, Rituxan, carboplatin, Other Names:, Paraplatin®, CBDCA, cyclophosphamide, Cytoxan, etoposide phosphate, Etopophos, cytarabine, ARA-C
Ohio State University Comprehensive Cancer Center
Lymphoma
12/09
12/11
NCT00003042: Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Active, not recruiting
2
41
US
filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, melphalan, mesna, paclitaxel, tamoxifen citrate, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation
City of Hope Medical Center, National Cancer Institute (NCI)
Breast Cancer
02/10
12/24
NCT00388102: Cyclophosphamide, Fludarabine, Total-Body Irradiation, and Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer or Other Disease

Recruiting
2
30
US
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, cytogenetic analysis, flow cytometry, laboratory biomarker analysis, umbilical cord blood transplantation, total-body irradiation
Memorial Sloan-Kettering Cancer Center
Leukemia, Lymphoma, Myelodysplastic Syndromes
03/10
 
JONIE, R000003949: Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with primary breast cancer

Recruiting
2
180
Japan
paclitaxel - Generic mfg., zoledronic acid - Generic mfg., epirubicin - Generic mfg., 5-fluorouracil - Generic mfg., cyclophosphamide - Generic mfg.
JONIE Study Group
Breast Cancer
 
 
NCT00398346: Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Recruiting
2
68
US
therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Secondary Myelofibrosis, Small Intestine Cancer
12/10
 
2010-023457-11: Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer

Ongoing
2
37
Europe
Cyclophosphamide, Coated tablet, Endoxan
UZ Leuven
advanced/recurrent ovarian and endometrial cancer
 
 
NCT00538031: Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed
2
52
US
cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Enduxan, celecoxib, Celebrex, SC-58635, YM 177
City of Hope Medical Center
Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
04/11
09/19
NCT00066300: Allogeneic Peripheral Stem Cell Transplantation Followed By Donor Lymphocyte Infusions in Treating Patients With Hematologic Cancer

Active, not recruiting
2
US
graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
 
 
2010-021111-17: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Not yet recruiting
2
53
Europe
Carfilzomib, PR-171, Tablet, Powder and solvent for solution for injection, ENDOXAN BAXTER*50CPR RIV 50MG, SOLDESAM
HOVON Foundation
newly diagnosed multiple myeloma patients
 
 
2009-017083-16: A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer

Ongoing
2
66
Europe
Powder for infusion*, Film-coated tablet, HERCEPTIN, XELODA, ENDOXAN BAXTER
GOIM GRUPPO ONCOLOGICO MERIDIONALE
Pre-or post-menopausal women with histologically proven, locally advanced (inoperable) or metastatic breast cancer.
 
 
2011-000796-14: COSMIC: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL

Ongoing
2
82
Europe
Ofatumumab, Fludarabine, Cyclophosphamide, Cyclophosphamide Injection, Bendamustine, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Coated tablet, Powder for solution for injection, Powder for concentrate for solution for infusion, Arzerra (Ofatumumab), Cyclophosphamide Injection
Leeds Teaching Hospitals NHS Trust, GlaxoSmithKline
Chronic Lymphocytic Leukaemia (CLL), Leukaemia is a cancer of the white blood cells. CLL is the most common type of Leukaemia. People with CLL make too many white blood cells called lymphocytes., Diseases [C] - Cancer [C04]
 
 
2010-023029-39: Plerixafor MM02 - Plerixafor plus G-CSF after chemotherapy for the mobilization of Peripheral Blood Stem Cells (PBSCs) in Multiple Myeloma (MM) patients undergoing Autologous Stem Cell Transplantation (ASCT) Plerixafor in associazione al fattore di crescita granulocitario (G-CSF) dopo chemioterapia per la mobilizzazione di cellule staminali nel sangue periferico (PBSCs) in pazienti con mieloma multiplo (MM) candidati a trapianto di cellule staminali autologhe (ASCT)

Ongoing
2
37
Europe
Solution for injection, Powder and solvent for solution for injection, Powder for solution for injection, Mozobil, GRANOCYTE 34*1F 33,6MIU+F 1ML, GRANULOKINE 30*1FL 30MU 1ML, ENDOXAN BAXTER*INIET 1FL 1G
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, Genzyme - fornitura gratuita IMP1
multiple myeloma mieloma multiplo, multiple myeloma mieloma multiplo, Diseases [C] - Cancer [C04]
 
 
NCT00850317: Fanconi Anemia Transplant Lacking Genotypically Identical Donor

Not yet recruiting
2
25
US
Miltenyi CliniMACs device
Children's Hospital Boston, Dana-Farber Cancer Institute
Fanconi Anemia
04/12
 
NCT01190787 / 2010-018873-39: Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Completed
2
150
Europe
velcade subcutaneous melphalan prednisone, Bortezomib, Alkeran, Deltacortene, velcade cyclophosphamide prednisone, Bortezomib,Endoxan, deltacortene, velcade prednisone, Bortezomib, deltacortene
European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
05/12
01/24
2012-001325-28: Phase II study in patients suffering from metastatic breast cancer Her2neg, The Line, randomized (1:1) with two arms. studio di fase II, in paziente affette da carcinoma della mammella metastatico Her2neg, I linea, randomizzato (1:1)a due bracci.

Ongoing
2
110
Europe
Solution for infusion
GOIM GRUPPO ONCOLOGICO MERIDIONALE, studio no-profit
patients wiyh metastatic breast cancer her2 negative first line treatment pazienti affette da carcinoma mammario metastatico Her2negativo in trattamento di I linea, breast metastatic cancer4 Her2 negative cancro alla mammella con metastasi Her2 negativo, in terapia di I linea, Diseases [C] - Cancer [C04]
 
 
2011-006259-12: Using magnetic resonance spectroscopy (MRS) to identify breast cancer patients who early respond to chemotherapy (after the first chemotherapy cycle) before breast cancer surgery.

Ongoing
2
50
Europe
Adrucil This treatment is considered as standard of care in the trial, Pharmarubicin This treatment is considered as standard of care in the trial, Endoxan This treatment is considered as standard of care in the trial, Cystocax This treatment is considered as standard of care in the trial, Neosar This treatment is considered as standard of care in the trial, Procytox This treatment is considered as standard of care in the trial, Taxotere This treatment is considered as standard of care in the trial, Taxol This treatment is considered as standard of care in the trial, Herceptin This treatment is considered as standard of care in the trial
Jules Bordet Institute, Les amis de l'Institut Bordet asbl
Early breast cancer requiring neoadjuvant chimiotherapy, Localised breast cancer that requires chemotherapy before breast surgery, Diseases [C] - Cancer [C04]
 
 
NCT00101101: Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

Completed
2
43
US
Cyclophosphamide, Cytoxan, Doxorubicin, adriamycin, Rubex, Vincristine, Oncovin, leurocristine, VCR, Prednisone, Deltasone, Liquid Pred, Meticorten, Orasone, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Autologous Tumor Cell-Based Vaccine, IL-2, interleukin-2, cytokine, aldesleukin
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), Lymphoma Research Foundation, Novartis
Lymphoma
10/12
06/21
NCT01346787: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Completed
2
58
Europe
CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
10/12
05/23
NCT01330212: PET-Guided Chemotherapy and Hormone Therapy in Treating Women With Previously Untreated Invasive Breast Cancer

Recruiting
2
60
US
bevacizumab, trastuzumab, capecitabine, cyclophosphamide, docetaxel, epirubicin hydrochloride, vinorelbine tartrate, gene expression analysis, microarray analysis, neoadjuvant therapy, positron emission tomography, therapeutic conventional surgery
Auxilio Mutuo Cancer Center
Breast Cancer
03/13
 
2012-005213-39: Study assessing efficacy of a Cisplatine – Métronomic yclophosphamide treatment in Patients with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxanes Etude évaluant l'Efficacité d'un Traitement par Cisplatine – Cyclophosphamide Métronomique Oral chez des Patientes Atteintes d'un Cancer du Sein Métastatique de Type Triple Négatif présentant une Résistance Secondaire aux Anthracyclines et Taxanes

Ongoing
2
35
Europe
CISPLATIN, CYCLOPHOSPHAMIDE, Concentrate and solvent for solution for infusion, Tablet, CISPLATIN, CYCLOPHOSPHAMIDE
CENTRE JEAN PERRIN, CENTRE JEAN PERRIN
Triple negative metastatic breast cancer resistant secondary to anthracyclines and taxanes Cancer du sein métastatique triple négatif résistant secondairement aux anthracyclines et taxanes, Triple negative metastatic breast cancer Cancer du sein métastatique, Diseases [C] - Cancer [C04]
 
 
2012-004118-33: evaluation of toxicity and efficacy of a transplantation program with high dose cyclophosphamide post transplant as GVHD prophylaxis in patients who underwent to allo transplant after RIC. valutare la tossicità e l’efficacia di una strategia trapiantologia comprendente boli di ciclofosfamide post trapianto, come profilassi per la GVHD, in pazienti affetti da LA o MDS ad alto rischio di età compresa tra 66 e 70 anni.

Ongoing
2
20
Europe
Powder for solution for injection, ENDOXAN BAXTER*INIET 1FL 1G
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE), ematologia
Elderly patients (66-70 years) with acute leukemia or high-risk MDS who, underwent allogenic transplant of peripheral hematopoietic progenitors after reduced-intensity conditioning. Pazienti anziani (66-70 anni), affetti da leucemia acuta o mielodisplasia ad alto rischio, sottoposti a trapianto allogenico di progenitori emopoietici periferici dopo condizionamento a ridotta intensità., Elderly patients (66-70 years) with acute leukemia or high-risk myelodysplasia, underwent allogenic transplant. Pazienti anziani (66-70 anni), affetti da leucemia acuta o mielodisplasia ad alto rischio, sottoposti a trapianto allogenico., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2012-002464-27: Blood Stem Cell transplantation with low dose chemo/radiotherapy for patients with High-Risk solid tumors using related identical donors or 50% compatible donors Trapianto di cellule staminali del sangue con basse dosi di chemio/radioterapia per pazienti con tumori solidi ad alto rischio utilizzando donatori familiari totalmente compatibili o compatibili per il 50%.

Ongoing
2
20
Europe
na, na, Powder for solution for injection, ENDOXAN BAXTER*INIET 1FL 500MG, ENDOXAN BAXTER*EV 1FL 1G
ISTITUTO EUROPEO DI ONCOLOGIA, Istituto Europeo di Oncologia
solid tumors metastatic or relapsed, resistant/refractory to conventional therapy tumori solidi metastatici o recidivati, resistenti/refrattari alle terapie convenzionali, Solid tumors with no chances of cure Tumori solidi senza ulteriore possibilità di cura, Diseases [C] - Cancer [C04]
 
 
NCT00295893: Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Active, not recruiting
2
121
US
cyclophosphamide, docetaxel, doxorubicin hydrochloride, Trastuzumab, Carboplatin, Paclitaxel
City of Hope Medical Center, National Cancer Institute (NCI)
Breast Cancer
12/13
12/24
2013-002684-25: Phase II study evaluating the combination of liposomal doxorubicin plus cyclophosphamide with trastuzumab followed by docetaxel plus trastuzumab as therapy to be performed before surgery (neoadjuvant chemotherapy) for patients with breast cancer more than 2 cm in size and possible involvement of the lymph nodes adjacent and with the receptor HER2 positive. Studio di fase II che valuta l'associazione della doxorubicina liposomiale più il ciclofosfamide con il trastuzumab, seguita da docetaxel più trastuzumab, come terapia da eseguire prima dell'intervento chirurgico (neoadiuvante) per pazienti con tumore della mammella di dimensioni oltre i 2 cm ed eventuale coinvolgimento dei linfonodi limitrofi e con il recettore HER2 positivo.

Ongoing
2
41
Europe
CYCLOPHOSPHAMIDE, DOCETAXEL, TRASTUZUMAB, Powder and solvent for dispersion for injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, MYOCET, DOCETAXEL
S.I.C.O.G. ONLUS, S.I.C.O.G. ONLUS
Local advanced breast cancer resectable, neoadjuvant setting Carcinoma mammario localmente avanzato operabile, in setting neoadiuvante, Cancer involving the breast than can be treated with chemotherapy before surgery Tumori avanzati del seno che possono essere trattati con chemioterapia, Diseases [C] - Cancer [C04]
 
 
NCT06531447: First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Active, not recruiting
2
200
RoW
Cisplatin, CDDP, Gemcitabine, Gemcitabine hydrochlorid, Doxorubicin, Cyclophosphamide, Paclitaxel
The National Center of Oncology, Azerbaijan
Breast Cancer
11/17
05/27
NCT00861705: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark Neo-adjuvant bevacizumab-containing therapy in TNBC
Dec 2013 - Dec 2013: Neo-adjuvant bevacizumab-containing therapy in TNBC
Active, not recruiting
2
454
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Onbevzi, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
08/14
02/25
2013-001800-13: Neoadjuvant phase II trial combining [3 FEC 100 followed by 3 docetaxel associated with trastuzumab plus pertuzumab] or [6 docetaxel, carboplatin associated with trastuzumab plus pertuzumab] according to TOP2A status in patients with T1c operable, HER2-positive breast cancer. Identification of pathological Complete Response (pCR) predictive factors.

Not yet recruiting
2
90
Europe
Solution for infusion, Powder for solution for injection, Powder for solution for infusion, FLUOROURACILE, EPIRUBICINE, ENDOXAN, DOCETAXEL, CARBOPLATINE, HERCEPTIN, PERJETA
UNICANCER, Roche Laboratories
Untreated, operable, non-metastatic and HER2-positive breast cancer (BC), Benign breast cancer, Diseases [C] - Cancer [C04]
 
 
2011-001690-62: A study comparing the standard treatment of transarterial chemoembolisation (TACE)plus low doses of chemotherapy (cyclophosphamide) with an immune cell derived vaccine

Ongoing
2
48
Europe
Cyclophosphamide, Autologous dendritic cells pulsed with HepG2 lysate matured with monophosphoryl lipid A, not applicable, Powder for solution for injection, Solution for infusion, Cyclophosphamide
University of Birmingham, NIHR-EME program
Hepatocellular carcinoma, Primary liver cancer, Diseases [C] - Cancer [C04]
 
 
SWOG-C10404, NCT00602459: Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Completed
2
418
Canada, US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI), Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, SWOG Cancer Research Network
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
12/14
04/23
2014-000782-53: This protocol is a phase II randomized, multicenter study designed to assess the safety and the efficacy of different carfilzomib combinations in newly diagnosed MM patients eligible for autologous transplantation (ASCT). Questo protocollo è uno studio di fase II randomizzato, multicentrico, per valutare la sicurezza e l'efficacia di differenti combinazioni di Carfilzomib in pazienti con nuova diagnosi di mieloma multiplo (MM), eleggibili al trapianto autologo (ASCT)

Ongoing
2
477
Europe
Carfilzomib, REVLIMID 5mg, REVLIMID 10 mg, REVLIMID 25 mg, PR-171, Powder for solution for injection, Capsule, hard, REVLIMID, REVLIMID 10mg, REVLIMID 25 mg
Università degli Studi di Torino-Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Onix Therapeutics, Inc., Celgene Pharmaceuticals
NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT Pazienti affetti da Mieloma Multiplo (MM) alla diagnosi, eleggibili al trapianto autologo, NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT Pazienti affetti da Mieloma Multiplo (MM) alla diagnosi, eleggibili al trapianto autologo, Diseases [C] - Cancer [C04]
 
 
2013-001226-25: A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple negative breast cancer Studio di Fase II, in aperto, in neo-adiuvante, randomizzato con regime chemioterapico classico rispetto al regime di chemioterapia ad alte dosi con trapianto autologo di cellule staminali nei pazienti con carcinoma mammario triplo negativo

Ongoing
2
74
Europe
Epirubicin, Cyclophosphamide, Docetaxel, THIOTEPA, Powder and solvent for solution for injection/infusion, Powder for injection, Concentrate for solution for infusion, Powder for concentrate for solution for infusion
ISTITUTI OSPITALIERI DI CREMONA, Fondazione FIRM Onlus
Triple Negative Breast Cancer patients with breast tumor >2,5 cm, no, Diseases [C] - Cancer [C04]
 
 
NCT01658969: Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery

Recruiting
2
48
US
Doxorubicin, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, Rubex, Cyclophosphamide, Cytoxan, CPM, CTX, Endoxan, Endoxana, Paclitaxel, Anzatax, Asotax, TAX, Taxol, Onxal™, Docetaxel, RP 56976, Taxotere, TXT, HER2Bi-armed activated T cells, laboratory biomarker analysis, therapeutic conventional surgery, Cytoxan®, Neosar®
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
06/15
11/15
NCT01946529: Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Active, not recruiting
2
24
US
vincristine, Oncovin(R), doxorubicin, Adriamycin(R), cyclophosphamide, Cytoxan(R), ifosfamide, Ifex(R), etoposide, VP-16, Vepesid(R), temozolomide, Temodar(R), temsirolimus, CCI-779, Torisel^TM, bevacizumab, rhumab VEGF, Avastin(R), sorafenib, BAY-43-9006, Nexavar(R), surgery, therapeutic conventional surgery, radiation, proton beam radiation therapy, external beam radiation therapy, brachytherapy
St. Jude Children's Research Hospital, University of Tennessee, University of Florida, Nemours Children's Clinic
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
08/15
07/26
AHOD03P1, NCT00107198: Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Active, not recruiting
2
188
Canada, US, RoW
Conventional Surgery, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
10/15
12/30
NCT01340430 / 2010-021600-24: Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

Completed
2
43
Europe
Trastuzumab, herceptin
Lucia Del Mastro,MD
HER-2 Positive Breast Cancer
12/15
01/22
2005-001569-33: First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamiento de primera línea con rituximab combinado con fluradabina, ciclofosfamida y Mitoxantrone (R-FCM) y mantenimiento con rituximab de pacientes con leucemia linfática crónica (LLC)

Ongoing
2
60
Europe
MabTheta, Ro 45-2294, MabThera®, MabThera®
Dept. Hematology, Hospital Clinic
Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated
 
 
2005-005967-27: Study pilot of metronomic chemotherapy with ciclofosfamide, celecoxib and desametasone in patients with diagnosis of carcinoma of the refractory ormon prostate in advanced stage appraisal pharmacodynamics

Ongoing
2
27
Europe
ENDOXAN BAXTER 50MG 50CPR, SOLDESAM 0,2 OS GTT 10ML, ENDOXAN BAXTER 50MG 50CPR, SOLDESAM 0,2 OS GTT 10ML
AZIENDA USL 6 LIVORNO ZONA LIVORNESE
ORMONO REFRACTORY CARCINOMA OF PROSTATE IN ADVANCED STAGE
 
 
2007-000065-38: METRONOMIC CHEMOTHERAPY WITH URACIL/TEGAFUR (UFT), CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB IN PRETREATED PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES: A PILOT CLINICAL STUDY WITH PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATIONS

Ongoing
2
36
Europe
ENDOXAN BAXTER*EV 1FL 1G, ENDOXAN BAXTER*50CPR RIV 50MG, CELEBREX*20CPS 200MG ACLAR TRA, UFT*42CPS, ENDOXAN BAXTER*EV 1FL 1G, ENDOXAN BAXTER*50CPR RIV 50MG, CELEBREX*20CPS 200MG ACLAR TRA, UFT*42CPS
AZIENDA USL 6 LIVORNO ZONA LIVORNESE
PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES
 
 
2006-000454-44: Etude prospective multicentrique de phase II évaluant l’adjonction du rituximab et du DepoCyte® en intrathécal au protocole de chimiothérapie C5R chez les patients âgés de 18 à 60 ans porteurs de lymphomes non hodgkiniens cérébraux primitifs et de lymphomes systémiques diffus à grandes cellules B avec envahissement neuro-méningé au diagnostic.

Ongoing
2
99
Europe
DepoCyte, Vincristine, Methotrexate, Adriamycine, Acide Folique, Cyclophosphamide, Prednisolone, Cytarabine, R0452994, DepoCyte, Mabthera, Vincristine, Methotrexate, Adriamycine, Acide Folique, Cyclophosphamide, Prednisolone, Cytarabine, DepoCyte, Mabthera, Vincristine, Methotrexate, Adriamycine, Acide Folique, Cyclophosphamide, Prednisolone, Cytarabine
Groupe d’Etude des Lymphomes de l’Adulte (GELA), The lymphoma Study Association (LYSA), , ROCHE SAS, Napp Pharmaceuticals research Limited
Patiens with primary cerebral or oculocerebral NHL not previously treated with chemotherapy or radiotherapy and diffuse large B-cell lymphomas, with cerebral and / or neuromeningeal involvement at diagnosis
 
 
2007-000699-18: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI

Ongoing
2
222
Europe
PREDNISONE, RITUXIMAB, DOXORUBICINE, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, METHOTREXATE, G-CSF, VINCRISTINE, IFOSFAMIDE, ETOPOSIDE, CYTARABINE, CARMUSTINE, MELPHALAN, autologous stem cells, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN
Hospices Civils de Lyon, Groupe d\'Etude des Lymphomes de l\'Adulte(GELA)
CD20+ diffuse large B-cell lymphoma
 
 
2006-006999-38: HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) SUPPORTED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC B-CELL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OR RELAPSE

Ongoing
2
25
Europe
MABTHERA, METHOTREXATE, ENDOXAN BAXTER, ETOPOSIDE TEVA, DEPOCYTE, MABTHERA, METHOTREXATE, ENDOXAN BAXTER, ETOPOSIDE TEVA, DEPOCYTE
OSPEDALE S. RAFFAELE
PATIENTS WITH SYSTEMIC B-CELL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OR RELAPSE
 
 
2007-003221-25: XINACT: To evaluate the benefit of specific drug combinations in reducing cancer tissue in the breast in women who have large breast cancers but confined to the breast and draining lymph glands.

Ongoing
2
120
Europe
Xeloda, Docetaxel Ebewe, Granocyte, Xeloda, Docetaxel Ebewe, Granocyte
United Lincolnshire Hospitals NHS Trust, , Roche Pharma UK; Sanofi Aventis Pharma UK; Chugai Pharma UK,
Large (>/=3 cm) or locally advanced breast cancers
 
 
2007-006025-27: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast cancer Studio di fase II di chemioterapia metronomica orale con ciclofosfamide e capecitabina combinata con bevacizumab e erlotinib (BEXE), piu\' trastuzumab nei tumori positivi per HER2/neu (BEXET)nel cancro della mammella avanzato

Ongoing
2
66
Europe
ENDOXAN BAXTER*50CPR RIV 50MG, XELODA*120CPR RIV 500MG, AVASTIN*INFUS 1FL 100MG 4ML, TARCEVA*30CPR RIV 150MG, HERCEPTIN*EV 1FL 150MG, ENDOXAN BAXTER*50CPR RIV 50MG, XELODA*120CPR RIV 500MG, AVASTIN*INFUS 1FL 100MG 4ML, TARCEVA*30CPR RIV 150MG, HERCEPTIN*EV 1FL 150MG
ISTITUTO EUROPEO DI ONCOLOGIA
advanced or metastatic breast cancer cancro della mammella localmente avanzato o metastatico
 
 
2007-003466-18: PHASE II TRIAL OF PRIMARY CHEMOTHERAPY WITH TRASTUZUMAB IN COMBINATION WITH DOCETAXEL FOLLOWED BY EPIRUBICIN-CYCLOPHOSPHAMIDE IN PATIENTS WITH HER2-OVEREXPRESSING OPERABLE BREAST CANCER

Ongoing
2
42
Europe
HERCEPTIN, FARMORUBICINA, TAXOTERE, ENDOXAN BAXTER, HERCEPTIN, FARMORUBICINA, TAXOTERE, ENDOXAN BAXTER
ISTITUTI FISIOTERAPICI OSPITALIERI
Primary chemotherapy in Her2-overexpressing operable breast cancer patient
 
 
2009-012048-18: �Fase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide � trastuzumab as preoperative treatment of locally advanced ER and PgR negative breast cancer�.

Ongoing
2
64
Europe
ENDOXAN BAXTER*50CPR RIV 50MG, HERCEPTIN, ENDOXAN BAXTER*50CPR RIV 50MG, HERCEPTIN
ISTITUTO EUROPEO DI ONCOLOGIA
Locally advanced breast cancer
 
 
2009-012944-17: Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (“Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.

Ongoing
2
31
Europe
90Y-ibritumomab tiuxetan, rituximab, prednisone, cyclophosphamide, vincristine, A07EA03, Zevalin, Mabthera, mabthera, Zevalin, Mabthera, mabthera
VUMC
follicular B cell NHL
 
 
2008-006381-29: Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer

Ongoing
2
200
Europe
Docetaxel, 5-Fluorouracil, Cyclophosphamide, Epirubicin, Taxotere, Fluorouracil, Endoxan, Farmorubicin, Taxotere, Fluorouracil, Endoxan, Farmorubicin
Universitätsmedizin Mainz
Eligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC.
 
 
2009-016453-17: Phase II study of preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide � trastuzumab and endocrine therapy for inflammatory breast cancer

Ongoing
2
59
Europe
ENDOXAN BAXTER*50CPR RIV 50MG, PACLITAXEL EB*INF FL100MG 6MG/, PACLITAXEL EB*INF FL300MG 6MG/, CARBOPLATINO EBE.*EV450MG/45ML, HERCEPTIN*EV 1FL 150MG, AVASTIN*INFUS 1FL 100MG 4ML, AVASTIN*INFUS 1FL 400MG 16ML, ENDOXAN BAXTER*50CPR RIV 50MG, PACLITAXEL EB*INF FL100MG 6MG/, PACLITAXEL EB*INF FL300MG 6MG/, CARBOPLATINO EBE.*EV450MG/45ML, HERCEPTIN*EV 1FL 150MG, AVASTIN*INFUS 1FL 100MG 4ML, AVASTIN*INFUS 1FL 400MG 16ML
ISTITUTO EUROPEO DI ONCOLOGIA
Inflammatory breast cancer
 
 
2009-015105-39: Etude de phase II évaluant une chimiothérapie combinant doxorubicine, cyclophosphamide, vindésine et acide valproïque dans les cancers bronchiques à petites cellules réfractaires ou récidivant après une chimiothérapie comportant des dérivés du platine et de l’étoposide.

Ongoing
2
11
Europe
valproate sodique, doxorubicine, VINDESINE, cyclophosphamide,
Centre Hospitalier Universiatire de Lille
les cancers bronchiques à petites cellules
 
 
2010-018389-22: A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compared with EC90 followed by weekly paclitaxel and trastuzumab (PX-T), as neoadjuvant therapy in patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm.

 
2
35
Europe
Lapatinib, Trastuzumab, GW572016, Tyverb, Herceptin, Tyverb, Herceptin
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A.
patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm.
 
01/11
2010-024266-21: A phase II study evaluating the role of the combination of Vinorelbine,cyclophosphamide and capecitabine administered metronomically, that means low doses daily orally, in patients with advanced breast cancer Studio di fase II che valuta il ruolo della combinazione di tre farmaci chemioterapici Vinorelbina, Ciclofosfamide e Capecitabina, somministrati in modalita\' metronomica, ossia a basse dosi date quotidianamente per bocca, alle pazienti affette da carcinoma della mammella metastatico

Ongoing
2
100
Europe
ENDOXAN BAXTER*50CPR RIV 50MG, NAVELBINE*1CPS 30MG, NAVELBINE*1CPS 20MG, XELODA*120CPR RIV 500MG, ENDOXAN BAXTER*50CPR RIV 50MG, NAVELBINE*1CPS 30MG, NAVELBINE*1CPS 20MG, XELODA*120CPR RIV 500MG
ISTITUTO EUROPEO DI ONCOLOGIA, Istituto Europeo Oncologia, PIERRE FABRE
Metastatic breast cancer Tumore della mammella metastatico
 
 
2010-024380-41: A pilot study to assess the effect of regulatory T-cell depletion on 5T4-containing MVA(TroVax®)vaccination in patients with inoperable metastatic colorectal cancer

Ongoing
2
54
Europe
Cyclophosphamide Tablets, TroVax, Not applicable, Cyclophosphamide 50 Tablets, Cyclophosphamide 50 Tablets
Cardiff University
Inoperable metastatic colorectal cancer
 
 
2010-020835-38: “A Phase II study evaluating the role of the combination of cisplatin and cyclophosphamide administered metronomically in patients with advanced breast cancer triple negative (Estrogen and progesterone receptors negative and c-erb B2 non overexpressed). “Studio di Fase II che valuta il ruolo della combinazione di due farmaci chemioterapici cisplatino e ciclofosfamide, somministrati in modalita\' metronomica nelle pazienti affette da carcinoma mammario triple negativo (recettori estro progestinici non espressi e c-erb B2 non sovra espresso)”.

Ongoing
2
48
Europe
ENDOXAN BAXTER*50CPR RIV 50MG, CISPLATINO TEVA IT*EV 100MG100, ENDOXAN BAXTER*50CPR RIV 50MG, CISPLATINO TEVA IT*EV 100MG100
ISTITUTO EUROPEO DI ONCOLOGIA, Istituto Europeo Oncologia
Advanced, triple receptor negative breast cancer Carcinoma mammario metastatico \'\'triple negative\'\'
 
 
2011-002751-34: An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients with Newly Diagnosed Multiple Myeloma

Ongoing
2
35
Europe
doxorubicin, Cyclophosphamide, Bortezomib, Lenalidomide, Adriamycin, Cyclophosphamide, Velcade, Revlimid, Adriamycin, Cyclophosphamide, Velcade, Revlimid
Vejle Hospital, Vejle Hospital
Patients with newly diagnosed symptomatic multiple myeloma according to the International Myeloma Working Group Diagnostic Criteria (Kyle 2009)
 
 
2012-001320-36: A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) compared to cyclophosphamide, velcade and dexamethasone (CVD)for first relapse or primary refractory mutiple myeloma patients.

Ongoing
2
300
Europe
Carfilzomib, Cyclophosphamide, Dexamethasone, Velcade, Dexamethasone, Velcade, Dexamethasone, Velcade
University of Leeds, Myeloma UK
multiple myeloma at the first relaspe of primary refractory disease stage
 
 
2012-003141-16: A trial to investigate treatment with EPOCH-R in patients with Burkitt lymphoma, by adapting the dose to the risk classification of the disease.

Ongoing
2
22
Europe
Etoposide, doxorubicin, Vincristine, Cyclophosphamide, Prednisolon, Rituximab, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisolone, Rituximab, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisolone, Rituximab
VU University Medical Center, VU University Medical Center
Burkitt lymphoma
 
 
2012-004998-53: Ofatumumab for the therapy of malignant lymphoproliferative disorder, called Waldenström’s macroglobulinemia (WM). Οφατουμουμάμπη για τη θεραπεία κακοήθους νεοπλασματικής διαταραχής, που ονομάζεται μακροσφαιριναιμία Waldenström.

Ongoing
2
39
Europe
Ofatumumab, GSK1841157, Arzerra, Arzerra
National and Kapodistrian University of Athens, National and Kapodistrian University of Athens
Relapsed or refractory Waldenström’s Macroglobulinemia. Υποτροπιάζουσα ή ανθεκτική μακροσφαιριναιμία Waldenström.
 
 
2013-004391-35: A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer. Studio clinico precedente all\'intervento chirurgico per valutare i regimi di Paclitaxel settimanale più Neratinib o Trastuzumab o Neratinib e Trastuzumab seguito da Doxorubicina e Ciclofosfamide con Trastuzumab postoperatorio in donne con tumore alla mammella HER2-positivo localmente avanzato.

Ongoing
2
33
Europe
Neratinib, PB-272; HKI-272, Herceptin, Herceptin
Puma Biotechnology Inc., Puma Biotechnology, Inc
Locally advanced HER2-positive breast cancer tumore alla mammella HER2-positivo localmente avanzato
 
 
NCT01027000: Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
2
68
US
rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Genentech, Inc., Biologics, Inc.
Leukemia, Lymphoma
01/16
04/23
2010-021962-31: KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC)

Ongoing
2
40
Europe
ketoconazole, Estramustine, Etoposid, Cyclophosphamide, Prednisolon, Sendoxan, Prednisolon, Sendoxan, Prednisolon
Bo Lennernäs
Men with castration resistant prostate cancer
 
 
2011-001512-65: No Ne

Ongoing
2
20
Europe
thalidomide, Celecoxib, Fenofibrate, Etoposide, Cyclophosphamide, Avastin, DepoCyte, Avastin, DepoCyte
Masaryk University, Masaryk University
recurrent or progressive medulloblastoma recidivující/progredující meduloblastom
 
 
2005-000656-33: A Phase I/II Study of Sirolimus (Rapamune TM) in Combination with Cyclophosphamide and Dexamethasone in Relapsed Myeloma

Ongoing
2
18
Europe
Rapamune, Cyclophosphamide, Rapamune, Cyclophosphamide 50 Tablets, Rapamune, Cyclophosphamide 50 Tablets
Royal Devon and Exeter NHS Foundation Trust
Plasma Cell Myeloma
 
 
2005-000104-13: A multicenter, placebo-controlled, double-blind randomised phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by six cycles of docetaxel, doxorubucin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer.

Ongoing
2
10
Europe
Bevacizumab, Doxorubicin, Cyclophosphamide, Docetaxel, RO4876646, Avastin, Doxorubicin, Cyclophosphamide, Docetaxel, Avastin, Doxorubicin, Cyclophosphamide, Docetaxel
Translational Oncology Research International
Stage II or Stage III breast cancer
 
 
2013-005387-25: no

Ongoing
2
10
Europe
DPX-Survivac, Solution for injection, DPX-SURVIVAC
Sapienza, University of Rome, Sapienza, University of Rome
Glioblastoma is the most common primary brain tumour in humans withthe most severe prognosis. Standard treatments consist primarily ofsurgery in order to debulk thetumoral mass, as well asradiochemotherapy to induce optimal local tumor control. However themedian overall survival (OS)is about 15 months, with 88% of patientsdead within 3 years il glioblastoma è il tumore cerebrale più diffuso, associato ad unaprognosi infausta. I trattamenti standard sono rappresentati dallachirurgia che permette di eradicare la massa tumorale e la radiochemioterapiaper il controllo della crescita tumorale. La sopravvivenzamedia è di circa 15 mesi, con l'88% di decessi entro i 3 anni., Glioblastoma is a malignant brain tumor, invasive, fast-growing and poorprognosis. Glioblastoma can be of primitive type or manifest as theprocessing of other brain tumors (secondary type). il glioblastoma è un tumore maligno del cervello, invasivo, a rapidacrescita e prognosi infausta. può essere di tipo primitivo o manifestarsicome trasformazione di altri tumori cerebrali., Diseases [C] - Cancer [C04]
 
 
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

Active, not recruiting
2
140
Europe
cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2
Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories
Primary Central Nervous System Lymphoma
05/16
05/26
NCT00792948: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Active, not recruiting
2
97
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Sirolimus, AY 22989, AY-22989, AY22989, RAPA, Rapamune, Rapamycin, SILA 9268A, SILA-9268A, SILA9268A, WY 090217, WY-090217, WY090217, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
06/16
01/25
2016-000581-31: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN BREAST CARCINOMA RESISTANT TO STANDARD TREATMENTS ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE - breast”

Ongoing
2
28
Europe
ENDOXAN, PROLEUKIN, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, RETE ONCOLOGICA DEL PIEMONTE E VALLE D'AOSTA
METASTATIC BREAST CANCER (MBC) CARCINOMA MAMMARIO METASTATICO, METASTATIC BREAST CANCER (MBC) CARCINOMA MAMMARIO METASTATICO, Diseases [C] - Cancer [C04]
 
 
2016-000578-39: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN METASTATIC COLON-RECTAL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – Colon-rectal STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE – colon-retto”

Ongoing
2
28
Europe
ENDOXAN, proleukin, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, Rete Oncologica del Piemonte e valle d'Aosta
COLORECTAL METASTATIC CANCER CARCINOMA COLON-RETTO METASTATICO, COLORECTAL METASTATIC CANCER CARCINOMA COLON-RETTO METASTATICO, Diseases [C] - Cancer [C04]
 
 
 

Download Options